Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that although there are a plethora of targeted agents in the drug development pipeline, identifying available breast cancer patients to test the new agents is a problem. According to the new Pharmacor report entitled Breast Cancer, Pfizer's Sutent -- which is in clinical trials -- could knock Roche/Chugai/Genentech's Avastin out of the breast cancer drug market. Sutent, a small molecule VEGF inhibitor, is identified as having great promise with sales forecasted to be in excess of $1.5 billion in 2016, and will help Pfizer become a major player in the oncology drug market.

"Sutent, an approved agent for the treatment of renal cell carcinoma, is currently under investigation in several Phase III trails in breast cancer, and will be launched into the breast cancer market place in 2009," said Joanne Graham, Ph.D., director at Decision Resources. "We forecast impressive sales for this multi-targeted agent and thought leaders report enormous enthusiasm and huge potential for this oral drug."

The report also finds that the patent expiry of multiple agents in the breast cancer market is the most significant constraint to growth. Key drugs that will be subject to generic price erosion throughout the forecast period include Sanofi-Aventis' Taxotere, Roche/Chugais' Xeloda, Lilly's Gemzar, AstraZeneca's Arimidex, Novartis' Femara, and Pfizer's Aromasin.

Reimbursement of costly targeted agents will limit their uptake, particularly in cost-constrained markets, such as the United Kingdom. However, as multiple high-priced drugs become available and their use in combination is indicated, reimbursement will increasingly be a barrier to uptake in all markets. Reimbursement will be particularly problematic for use of such agents in late stage disease, if only modest clinical gains are achieved.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (www.decisionresources.com) is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

  All company, brand, or product names contained in this document may be      trademarks or registered trademarks of their respective holders.    For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Centers for Medicare & Medicaid Services Reach Agreement with Major Insurers to Cease Marketing of Private Fee-for-Service

View Now